mn@@,00ffering,G00d,b@@d,general business related,,M/A Other
in talks,,achieves key milestone,dividend suspended,mark down,,have stalled
drops talks,,key milestone,suspend dividends,prices,,announces completion of merger
to be aquired,,anounces restructuring plan,grand jury subpoena,price,,
hired advisor,,restructuring plan,Did Not Meet Primary Endpoint,marked down,,
cash and stock,,signed a supply contract,Negative Trend Vote,subscription,,
seek sale,,Expands its Collaboration with,sexual misconduct,cut,,
buyout,,Announces FDA Acceptance of New Drug Application,sexual harassment,supply,,
tender offer,,Announces FDA Acceptance,internal investigation,demand,,
takeover,,FDA Says It Will Review Treatment,issued subpoenas,probe,,
advanced talks,,Gets FDA Acceptance,issues subpoenas,,,
cash offer,,FDA Acceptance,issued subpoena,,,
stock offer,,Accepted for Regulatory Review,issues subpoena,,,
license agreement,,receive regulatory milestone,subpoena,,,
explore options,,Significant milestone,subpoenaed,,,
renewed takeover speculation,,Announces Definitive Asset Purchase Agreement,declaratory judgment,,,
merger,,overwhelming positive response,postpones release,,,
got approach from,,Announce Strategic Collaboration,won't release financial results,,,
hire bank to weigh sale,,Collaboration To Develop,did not meet its primary endpoint,,,
in talks with,,announced a collaboration with,said to be investigating,,,
held takeover talks,,Investment Will Strengthen Balance Sheet,doj investigation,,,
talks are on hold,,Support Transition to High Performance,us probe,,,
deal would value,,Announces Transformational,conducting investigation,,,
have been discussing ,,extended adjuvant treatment,announces investigation,,,
exploring sale,,Announces FDA Approval,deal may be off,,,
nearing deal,,announces breakthrough discovery,could turn its back on the planned acquisition,,,
entered into a definitive agreement,,Announces Effective License,evidence of wrongdoing,,,
acquire a significant position,,meets primary endpoint,investigating potential breaches,,,
get interest from,,announces exclusive distribution,may back out of,,,
draw interest from,,announced a network services agreement,allegations prove to be conclusive,,,
drawing interest from,,partner to extend payments to,withdraw from the contract,,,
getting interest from,,reports topline phase,announces probe,,,
bidders,,announces topline phase,possible data breaches,,,
suitors,,demonstrates comparable efficacy,hamper a deal,,,
acquiring,,superiority clinical trial,may be in doubt,,,
acquirer,,announces major expansion,may be kaput,,,
eyeing,,corporate milestone,data integrity issues,,,
purchase,,announces strategic initiatives,investigate alleged breaches,,,
contemplating,,to enhance shareholder value,investigation by acquirer,,,
,,demonstrates improved,fda breaches,,,
,,announced positive top-line results,data breaches,,,
,,reports favorable results from,independent investigation,,,
,,icahn stake,refusal to file letter,,,
,,icahn acquires,fda refusal,,,
,,icahn has acquired,fda turns down,,,
,,a major breakthrough for,fda rejects,,,
,,european commission awards,fda refuses,,,
,,confidential definitive agreement,would not accept a drug marketing application,,,
,,positive preclinical study,fda declines to,,,
,,announces positive topline results,sec investigation,,,
,,primary endpoint achieved,sec probe,,,
,,primary endpoints achieved,to investigate its,,,
,,achieved primary endpoint,ordered to investigate,,,
,,achieved primary endpoints,ftc investigates,,,
,,announces 'positive' topline reults,ftc recently issued subpoenas,,,
,,trial met primary and secondary endpoints,issued subpoenas,,,
,,acquires an exclusive license,issued subpoena,,,
,,acquires license to late stage,ftc probe,,,
,,announces fda clearance,ftc probes,,,
,,receives fda clearance,us foods sue,,,
,,gets fda clearance,us foods sues,,,
,,announces positive top-line results,us foods allege,,,
,,met primary endpoint,did not meet endpoints,,,
,,met its primary endpoint,did not meet co-primary endpoints,,,
,,announces 'positive' top-line results,discontinue development program,,,
,,reports positive results in late-stage,expects to discontinue development of,,,
,,received strategic investment from,fails to meet co-primary endpoints,,,
,,appoints jon 'dr. j' najarian,fails to meet endpoints,,,
,,fda grants,trials miss endpoints,,,
,,wins fda breakthrough,termination of merger agreement,,,
,,key technology milestones,doj block the merger,,,
,,key resistant starch wheat technology milestones,termination of a material definitive agreement,,,
,,reports positive topline results,doj block,,,
,,positive drug trial results,terminate merger agreement,,,
,,met all of its primary objectives,intends to open investigation,,,
,,achieved all primary and key secondary endpoints,terminate merger deal,,,
,,reports positive phase 2 results,abandons merger,,,
,,met primary and all secondary endpoints,fails to meet primary endpoint,,,
,,met endpoints with statistical significance,did not meet its pre-specified primary endpoint,,,
,,achieved statistically significant improvement,have stalled,,,
,,receives regulatory approval,talks stall,,,
,,breakthrough therapy designation,did not meet the non-inferiority margin of the cfa primary endpoint,,,
,,announces top-line results,did not achieve the primary endpoint,,,
,,federal communications commission (fcc) certification,did not acieve primary endpoint,,,
,,federal communications commission certification,treatment study disappoints,,,
,,announces continuing positive data from,failed drug trial,,,
,,key clinical development objectives were met,suspend further development of,,,
,,entered into a license agreement,placed on clinical hold,,,
,,breakthrough discovery,places clinical hold,,,
,,achieved a regulatory approvable endpoint,will not seek accelerated approval,,,
,,support fda marketing application,won't seek accelerated approval,,,
,,epa approves,extension of pdufa date,,,
,,accepted into european evaluation process,discontinues phase,,,
,,positive research results,postponing decision on initiation of phase,,,
,,reports top-line interim safety and biopsy findings,did not meet the primary endpoint,,,
,,extremely pleased with the outcome,may have spread hepatitis a,,,
,,entered into a definitive purchase agreement,infected with hepatitis a,,,
,,to acquire majority of,suspension of audit report,,,
,,to purchase significant part of,doj porbing,,,
,,to buy significant part of,ftc files suit,,,
,,clinically meaningful benefit observed,ftc said to file,,,
,,achieved a highly statistically significant improvement,ftc accuses,,,
,,achieved primary and key secondary endpoints,ftc charges,,,
,,achieved primary and secondary endpoints,ftc lawsuit,,,
,,announce positive topline results,serious adverse events,,,
,,announced today that they will be partnering with a,saes,,,
,,Data Showing Improvement in Immune Function,placed a clinical hold,,,
,,Decreased Infection Rates,fda complete response letter,,,
,,statistically significant decrease in,complete response letter,,,
,,Reduction in Overall Tumor Volume,does not provide substantial evidence of effectiveness,,,
,,signs exclusive ground-breaking,serious adverse event,,,
,,demonstrating HBsAg reductions,concerning immune response,,,
,,announces approval by the FDA,announces discontinuation of,,,
,,announces positive results from phase,primary endpoint was not achieved,,,
,,a promising and differentiated therapeutic agent,nasdaq delisting,,,
,,consistently observed across all measures,delisted from nasdaq,,,
,,statistically significant and clinically relevant reductions,FDA to Propose Ban,,,
,,we are extremely pleased to announce,due to recent demand changes,,,
,,we view this outcome as impressive,due primarily to lower factory utilization,,,
,,announce equity investment,on expense control and lower incentive compensation,,,
,,announces strategic alternatives  process,expects sequential revenue to be down,,,
,,issues statement,revenue to be down,,,
,,Announces Vehicle Pre-Orders,no longer looking at,,,
,,strong pre-order demand,only interested in partial stake,,,
,,I am pleased to update our investors,decided not to pursue,,,
,,Department Of Justice Clears,not bidding for,,,
,,doj clears,not to submit a New Drug Application,,,
,,Exploring Potential Business Combinations,,,,
,,FDA Agrees with,,,,
,,receives New York State hemp licence,,,,
,,receives hemp licence,,,,
,,Announces Removal of Partial Clinical Hold,,,,
,,"sells portion of"" ""enters into binding term sheet",,,,
,,Announces the Establishment of,,,,
,,Data Demonstrating Significant Synergy,,,,
,,Receives Positive Feedback from,,,,
,,Initiates Review Of Strategic Alternatives,,,,
,,Receives Approval to Proceed with,,,,
,,Announce Strategic Partnership,,,,
